本公告乃中國同輻股份有限公司（「中國同輻」或「本公司」）自願發出以使股東及潛 在投資者知悉本公司之最新業務進展。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 CHINA ISOTOPE & RADIATION CORPORATION 中國同輻股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1763） 自願性公告 中國同輻呼氣診斷產品榮獲國家級製藥業單項冠軍 本公司董事會（「董事會」）欣然宣佈，近日，中國同輻附屬公司深圳市中核海得威 生物科技有限公司憑藉核心產品「尿素[13C/14C]呼氣試驗藥盒」成功入選國家級製 造企業並榮獲「製藥業單項冠軍」。 中國同輻始終聚焦於醫用同位素應用中的尿素[13C]及[14C]呼氣診斷細分領域，生 產的尿素[13C]及[14C]呼氣試驗產品用於檢測幽門螺旋桿菌，產品覆蓋國內2萬餘 家終端客戶，銷往90個國家和地區，市場佔有率連續多年穩居行業前列。 中國同輻將進一步強化科技創新主體地位，持續深耕 ...

Core Viewpoint - China Tongru (01763.HK) experienced a significant increase in stock price, rising over 10% in the afternoon trading session, indicating strong market interest and potential investor confidence [1] Group 1 - The stock price of China Tongru rose by 10.21%, reaching HKD 20.94 [1] - The trading volume for China Tongru was reported at HKD 24.42 million [1]

Core Viewpoint - China Tongru (01763) experienced a significant stock increase of over 10% following the launch of its carbon isotope product and the second phase of its stable isotope base project in Tongcheng, Anhui, which is expected to enhance domestic production capabilities in the medical isotope sector [1] Group 1: Company Developments - The launch event on October 31 marked the initiation of a project that will produce 2,000 kilograms of high-abundance 13CO gas and 4,000 kilograms of 13C urea raw materials annually [1] - The high-abundance 13CO gas is a critical raw material used in urea breath tests for detecting Helicobacter pylori infections [1] - The project signifies a shift from reliance on imported 13CO gas for urea breath diagnostic materials, establishing a fully autonomous supply chain in the medical stable isotope carbon field in China [1] Group 2: Industry Impact - The establishment of this production line is expected to provide a solid foundation for creating a safe and reliable high-end medical isotope supply chain in China [1] - The project represents a comprehensive control over the entire industry chain from key raw materials to end products in the medical stable isotope sector [1]

Core Viewpoint - China Tongru (01763) experienced a significant stock increase of over 10%, reaching HKD 20.94 with a trading volume of HKD 24.42 million, following the launch of its carbon isotope product and the second phase of its stable isotope base project in Tongcheng, Anhui on October 31 [1] Group 1: Project Launch and Production Capacity - The newly launched project is expected to produce 2,000 kilograms of high-abundance 13CO gas and 4,000 kilograms of 13C urea raw materials annually, along with other raw materials for gastrointestinal disease treatment drugs [1] - The high-abundance 13CO gas is a critical raw material used in the urea breath test for detecting Helicobacter pylori infections [1] Group 2: Market Impact and Self-Sufficiency - The launch of high-abundance 13CO gas and urea products signifies China's break from long-term reliance on imports for the 13CO gas used in urea breath diagnostics [1] - This development allows China to achieve a fully self-controlled industrial chain in the medical stable isotope carbon sector, from key raw materials to end products, thereby establishing a solid foundation for a safe and reliable high-end medical isotope supply chain [1]

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國同輻股份有限公司 呈交日期: 2025年11月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01763 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 79,968,800 | RMB | | 1 | RMB | | 79,968,800 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 79,968,800 | RMB | | 1 | RMB | | 79,968,800 | | 2. 股份分類 ...

Core Viewpoint - China Tongru (01763) experienced a significant stock price increase of over 7% during trading, attributed to the launch of high-purity 13CO gas and urea products, marking a shift towards self-sufficiency in the medical stable isotope carbon sector [1] Company Overview - China Tongru is a specialized company under China National Nuclear Corporation, focusing on nuclear technology applications, including the development, production, and sales of nuclear medicine, radiation source products, and related services [1] - The company has established a comprehensive layout in the nuclear medicine field, with a network of 37 medical centers and 7 R&D production bases by December 31, 2024, positioning itself as a leader in China's nuclear medicine sector [1] Industry Impact - The launch of high-purity 13CO gas and urea products signifies China's ability to break free from reliance on imported materials for urea breath diagnostic agents, achieving full control over the entire industry chain from key raw materials to end products [1] - This development enhances the company's status as a leading enterprise capable of managing the complete supply chain for breath test products in the medical stable isotope carbon field [1]

Core Viewpoint - China Tongru (01763) experienced a significant stock price increase, rising over 7% during trading and closing at 20.16 HKD, with a transaction volume of 10.36 million HKD, following the launch of its high-abundance 13CO gas and urea products, marking a milestone in the domestic production of medical stable isotopes [1] Company Overview - China Tongru is a specialized company under the China National Nuclear Corporation, focusing on nuclear technology applications, including the development, production, sales, and services related to nuclear medicine, radiation source products, and nuclear medical equipment [1] - The company has established a comprehensive layout in the nuclear medicine sector, with a network of 37 medical centers and 7 R&D production bases by December 31, 2024, positioning itself as a leading enterprise in China's nuclear medicine field [1] Industry Impact - The successful launch of the high-abundance 13CO gas and urea products signifies China's achievement in breaking the long-standing reliance on imports for the raw materials used in urea breath diagnostic tests, enabling full domestic control over the entire industry chain from key raw materials to end products [1] - This development positions China Tongru as a leading enterprise that fully masters the entire industry chain of breath test products, enhancing its competitive edge in the medical stable isotope market [1]

Core Viewpoint - The launch of the stable isotope base phase II project by China Tongfu marks a significant advancement in the domestic production of high-abundance 13CO gas and 13C urea raw materials, reducing reliance on imports and establishing a comprehensive domestic supply chain for medical stable isotopes [1] Group 1 - The project, initiated on October 31, aims to produce 2000 kilograms of high-abundance 13CO gas and 4000 kilograms of 13C urea raw materials annually [1] - High-abundance 13CO gas is a critical raw material used in the urea breath test for detecting Helicobacter pylori infections [1] - The launch signifies China's achievement in establishing a fully autonomous and controllable supply chain in the medical stable isotope carbon sector, from key raw materials to end products [1]

Core Viewpoint - China Tongru (01763) has made a significant breakthrough in the field of stable isotopes by launching carbon isotope products, marking China's advancement in high-end technology and reducing reliance on imports for key medical materials [1] Group 1: Product Launch and Significance - The launch of high-abundance 13CO gas and carbon-13 urea raw materials positions China as one of the few countries capable of producing these essential components for medical applications [1] - The new products will eliminate China's complete dependence on imports for 13CO used in urea breath tests for detecting Helicobacter pylori infections, enhancing domestic production capabilities [1] Group 2: Industry Impact and Future Projects - The announcement coincides with the initiation of the second phase of the stable isotope base project, which will ensure a stable supply of high-abundance 13CO gas and other raw materials for gastrointestinal disease treatments [1] - This development is expected to significantly contribute to national health improvement and the high-quality development of medical isotopes, aligning with the "Healthy China" initiative [1]

Core Viewpoint - China Tongfu (01763) has made a significant breakthrough in the stable isotope field by launching carbon isotope products, positioning China among the few countries capable of producing high-abundance CO gas and carbon-13 urea raw materials [1] Company Summary - The launch of high-abundance CO gas, a key raw material for urea breath tests used to detect Helicobacter pylori infections, marks the end of China's complete reliance on imports for this material [1] - China Tongfu has enhanced its research and production capabilities in stable isotope products, establishing itself as a leading enterprise with a complete grasp of the entire industrial chain for breath test products [1] Industry Summary - The initiation of the second phase of the stable isotope base project will enable China Tongfu to ensure a stable supply of high-abundance CO gas, carbon-13 urea raw materials, and other raw materials for gastrointestinal disease treatment [1] - This development is expected to significantly contribute to improving national health standards, promoting high-quality development of medical isotopes, and supporting the "Healthy China" initiative [1]